CHC MontLegia
Verified site
Liege, Belgium
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial focuses on patients with pMMR/MSS colon cancer, a type of colon cancer that can be removed by surgery and has specific genetic characteristics. The treatment being tested combines an infusion of pembrolizumab, a medication that helps the immune system recognize and attack cancer cells, with an infusion of Porustobart, a new drug being studied for its ability to stop tumor growth.
The purpose of the study is to see how many patients have a major reduction in tumor size before surgery when given these medicines. Participants receive several doses of the two infusions over a short period before their planned operation, after which the surgery is performed to remove the tumor. Researchers will then monitor the patients for recovery and any side effects.
After surgery, patients are followed for several months to check for any return of cancer and to assess overall health. The study tracks how well the treatment was tolerated and whether it helped achieve a complete disappearance of detectable tumor tissue. Important terms include neoadjuvant, which means treatment given before surgery, and major pathologic response, which describes a situation where only a very small amount of tumor remains.
The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.
13 criteria
16 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Liege, Belgium
Leuven, Belgium
Woluwe-Saint-Lambert, Belgium
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an intravenous medicine that helps the immune system recognize and attack cancer cells. In this study it is given before surgery (neoadjuvant) to see if it can shrink or eliminate the tumor in patients with colon cancer that has a normal mismatch‑repair system. Researchers are testing different timing schedules of the infusion to find the best way to use the drug.
is a new experimental drug that is also given by IV infusion before surgery. It is being studied together with pembrolizumab to see if the combination works better than pembrolizumab alone. The trial is looking at how well Porustobart helps the tumor respond to treatment and whether it is safe for patients.
It is given by intravenous infusion, meaning the medication is mixed in a liquid and slowly injected into a vein. Pembrolizumab is an approved cancer drug that is widely used and studied in many medical papers. It is mainly used to treat several cancers, including certain types of colon cancer that cannot be removed by surgery. It works by blocking a protein called PD‑1, which lets the body’s immune cells see and attack tumor cells, and it belongs to the class of immune‑checkpoint inhibitors.
It is also given by intravenous infusion, a liquid that is injected directly into a vein. Porustobart is an experimental medicine that is still being tested in clinical trials and has not yet received regular approval. It is being examined for use together with pembrolizumab in patients with resectable colon cancer that has normal mismatch‑repair genes. It is thought to act on a specific cell pathway that slows tumor growth, placing it in the group of targeted cancer therapies.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.